Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

NCT04134884 is registered in ClinicalTrials.gov with Kathy Miller as lead sponsor.

NCT NCT04134884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04134884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Lead sponsor
Kathy Miller
Phase
Phase 1
Overall status
Completed
Start date
April 1, 2020
Completion date
March 14, 2024
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor positive tumor, metastatic breast cancer, triple negative breast cancer